Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Earnings for Minerva Surgical, Inc. (UTRS)
Earnings in 2022 (TTM): $-34,101,000
According to Minerva Surgical, Inc.'s latest financial reports the company's current earnings (TTM) are $-34,101,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Minerva Surgical, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-34,101,000 | $-34,112,000 |
| 2021 | $-21,455,000 | $-21,464,000 |
| 2020 | $-18,395,000 | $-18,263,000 |
| 2019 | $-52,046,000 | $-69,796,000 |